Manufacturer:
CMP Pharma
Route of Administration:
Oral
Site of Care:
Outpatient
Website:
Approved Indication:
treatment of pulmonary arterial hypertension (WHO Group 1) to improve exercise ability
Conditions:
- Pulmonary Arterial Hypertension